Medicine and Dentistry
Enzalutamide
100%
Cell Line
100%
Cancer Cell
100%
Prostate Cancer
100%
Alisertib
66%
Ovarian Cancer
33%
Clinical Trial
33%
Cisplatin
33%
Xenograft
33%
BRCA1
33%
In Vitro
33%
Targeted Therapy
33%
22Rv1 Cell Line
33%
PARP Inhibitor
33%
IC50
33%
Cell Killing
33%
DNA Damage Response
33%
Keyphrases
Prostate Cancer Cells
100%
Aurora Kinase A (AURKA)
100%
Enzalutamide
60%
Alisertib
40%
Chemotherapy
20%
PDX Model
20%
Ovarian Cancer Cells
20%
In Vitro Assay
20%
Clinical Benefit
20%
Cisplatin
20%
IC50
20%
Conventional Chemotherapy
20%
Mitosis
20%
Breast Cancer Susceptibility Gene 1 (BRCA1)
20%
DNA Damage Response
20%
PCa Cells
20%
Molecular Features
20%
AURKA Inhibitor
20%
Xenograft Model
20%
22Rv1
20%
Cell Killing
20%
Toxicity Issues
20%
Damage Test
20%
AR-targeted Therapy
20%
Phase II Clinical Trial
20%
PARP Inhibitor (PARPi)
20%
Novel Functions
20%
Cell Line Panel
20%
Pharmacology, Toxicology and Pharmaceutical Science
Enzalutamide
100%
Prostate Cancer
100%
Alisertib
66%
Chemotherapy
66%
Clinical Trial
33%
Ovary Cancer
33%
Cisplatin
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
33%
IC50
33%